Contents
On this page
- Quick answer
- Overview: what is current in November 2026
- The AWMF S-classification
- IQWiG evidence reports and Innovationsfonds funding
- What S3 guidelines require from evidence reviews
- Systematic, rapid and scoping reviews compared
- Grading evidence and recommendations
- Structured consensus and conflicts of interest
- Validity, updating and living guidelines
- Worked example: from key question to graded recommendation
- Checklist for evidence review teams
- Conclusion
- Frequently asked questions
- Sources
InsightsRegulatory Updates
Regulatory update
AWMF S3 Guidelines: What the Rules Require from Systematic, Rapid and Scoping Reviews
The S-classes, Regelwerk 2.2, IQWiG evidence reports, GRADE and German recommendation wording, consensus thresholds, conflict-of-interest rules and a delivery checklist for review teams, current as of November 2026.
- Germany
- Guidelines
- Systematic review
- Regulatory update
- Rulebook
- AWMF Regelwerk 2.2 (May 2025)
- S3 means
- Systematic evidence review plus structured consensus
- IQWiG role
- Evidence reports for guideline groups since 2020
- Validity
- Maximum 5 years; living guidelines updated at least every 12 months
At a glanceRegulatory Updates
Explore systematic review servicesDiscuss your project
Quick answer
- AWMF guidelines are recommendations developed by Germany’s scientific medical societies under the AWMF Regelwerk (version 2.2, 2025), not statutory regulation1.
- S3 is the only class that combines a systematic evidence review with structured consensus by a representative panel, so every key question needs a documented search, selection, appraisal and evidence summary1.
- Since 2020, IQWiG can prepare evidence reports for guideline groups under § 139a(3) no. 3 and § 139b(6) SGB V; the guideline group still formulates and votes on the recommendations2.
- Rapid reviews can feed S3 work if every shortcut is stated3; scoping reviews help refine key questions but rarely support graded recommendations on their own.
Overview: what is current in November 2026
The AWMF (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, the Association of the Scientific Medical Societies in Germany) is the umbrella body for 185 scientific medical societies, according to its 2025 annual report4. Through its rulebook, the AWMF Regelwerk, it sets the methodological standards a guideline must meet to be classified and published in the AWMF guideline register15.
AWMF guidelines are professional-society recommendations, not regulation. They are not laws and are not issued by a government agency. They carry weight because they describe the scientifically supported standard of care, and because statutory bodies sometimes draw on them.
This article explains what the Regelwerk asks of the evidence behind an S3 guideline, how systematic, rapid and scoping reviews fit in, and where IQWiG evidence reports and Innovationsfonds funding come in.
Status as of 22 November 2026
- AWMF Regelwerk version 2.2 (summary of changes dated 22 May 2025) is the current rulebook. According to AWMF’s summary, the main changes were notes on the new digital registration procedure, a clarified consensus-strength table, clarified requirements for neutral moderation, and new help documents (for example on statutory funding options and digital tools for consensus)1.
- IQWiG General Methods version 8.0 took effect on 19 December 2025; the English translation followed on 1 July 20266.
- IQWiG’s generic project outline for evidence reports on intervention questions is at version 2.0 (30 June 2025)7.
- Only the documents published at awmf.org/regelwerk are valid. Check them, and the methods report of your own guideline, before you rely on a specific rule.
The AWMF S-classification
The Regelwerk classifies guidelines by two things: how systematically the evidence was searched and appraised, and how formally consensus was reached1.
Table 1. AWMF guideline classes (summarised from the AWMF Regelwerk)
| Class | Basis | Systematic evidence review | Structured consensus with a representative panel | How recommendations are graded |
|---|---|---|---|---|
| S1 | Recommendations of an expert group | No | No (informal consensus) | Not graded |
| S2k | Consensus-based | No | Yes | Wording only (soll / sollte / kann), with no evidence or recommendation grades |
| S2e | Evidence-based | Yes: systematic search, selection and appraisal | No | Linked to the appraised evidence (evidence levels) |
| S3 | Evidence- and consensus-based | Yes | Yes | Recommendation grades, plus evidence certainty or levels |
S2e versus S3. An S2e guideline must rest on a systematic evidence review and link each recommendation to the appraised evidence, but it is not agreed through a structured consensus process with a representative panel. S3 adds that consensus step. In practice the evidence work for S2e and S3 is similar, so review teams should plan for the same documentation either way.
Two large programmes produce many S3 guidelines and publish detailed methods reports that are useful models: the Leitlinienprogramm Onkologie (German Guideline Program in Oncology)8 and the Nationale VersorgungsLeitlinien (NVL, National Disease Management Guidelines)9.
IQWiG evidence reports and Innovationsfonds funding
Since 2020, the Institute for Quality and Efficiency in Health Care (IQWiG) has had a statutory task under § 139a(3) no. 3 and § 139b(6) SGB V (German Social Code, Book V) to support guideline development with evidence research2. The process, as IQWiG describes it:
- The AWMF proposes guideline topics and questions to the Federal Ministry of Health (BMG).
- If the BMG accepts a proposal, it commissions IQWiG to prepare an evidence report (Evidenzbericht) on the agreed questions.
- IQWiG also invites societies to contact it directly, before or alongside registering the project with the AWMF, which remains the main point of contact2.
IQWiG’s generic project outline for intervention questions sets out the report structure: question formulation agreed at a kick-off with the guideline coordinators and the AWMF, systematic searches, study selection, data extraction, risk of bias assessment and a GRADE assessment of the certainty of evidence, presented in evidence profiles per outcome7. The General Methods describe how IQWiG produces these reports6. IQWiG does not write the recommendations: the guideline group still formulates, grades and votes on them.
Published S3 guidelines show how this works in practice. The S3 guideline on vaginal birth at term (AWMF registry no. 015/083), for example, reports that it used IQWiG evidence reports to assess the quality of evidence10.
Funding. Since 2020, the Innovationsfonds run by the Federal Joint Committee (G-BA) has also funded the development and updating of selected guidelines where there is a particular need in care11. Budgets and eligibility are set in each funding announcement, so check the current call rather than relying on past amounts.
For the wider German HTA picture, see our guides to the IQWiG General Methods on meta-analysis and the EU HTA Regulation and joint clinical assessments.
Evidence reviews for German guideline groups
Pubrica’s systematic review team supports guideline groups with PICO key questions, documented searches, screening, risk of bias assessment, GRADE evidence profiles and rapid reviews that list every shortcut, in a format ready for the Leitlinienreport. We work to the group’s methods plan and the current AWMF Regelwerk but are not affiliated with or accredited by the AWMF. The guideline group keeps ownership of and responsibility for the recommendations, and timelines are agreed project by project.
What S3 guidelines require from evidence reviews
At S3 level, each key question must be answered with systematically identified and appraised evidence, and the whole process must be documented in the guideline report (Leitlinienreport) published alongside the guideline1. Whether the evidence comes from your own team, a commissioned contractor or IQWiG, guideline groups typically expect:
- Key questions agreed by the guideline group and structured with PICO (population, intervention, comparison, outcome) or an adapted framework for diagnostic, prognostic or qualitative questions.
- Patient-relevant outcomes, prioritised with input from patient representatives in the guideline group.
- A systematic search with documented strategies, sources and dates. Many groups start by searching for high-quality guidelines and systematic reviews, then update them with primary studies. Report the search in line with PRISMA-S.
- Transparent selection against prespecified criteria, with reasons for exclusion and a flow diagram (see our PRISMA 2020 flowchart guide).
- Risk of bias or methodological quality assessment with a recognised tool (see which risk of bias tool to use).
- Evidence summaries: evidence tables and, increasingly, GRADE evidence profiles or summary-of-findings tables per outcome.
Adapting existing guidelines. A group does not always have to start from scratch. Where a recent, high-quality guideline exists, recommendations can be adopted or adapted using a documented method such as ADAPTE12 or GRADE-ADOLOPMENT, which combines adoption, adaptation and de novo development within GRADE Evidence to Decision frameworks13. AWMF has published a help document on adoption and adaptation of guideline recommendations (2023)1. The source guideline is then appraised and its evidence updated, and the methods must still be reported in the Leitlinienreport.
Systematic, rapid and scoping reviews compared
The Regelwerk asks for a systematic evidence base at S3 level, but it does not set out a separate rulebook for each review type. Table 2 is therefore practice guidance drawn from methods literature and guideline methods reports, not a list of AWMF rules. Agree the approach for each key question with the guideline group and its AWMF advisor, and record it in the Leitlinienreport.
Table 2. How review types typically support guideline development (practice guidance, not Regelwerk rules)
| Aspect | Systematic review | Rapid review | Scoping review |
|---|---|---|---|
| Typical role | Main evidence base for graded recommendations | Faster evidence for urgent questions or updates, including living guidelines | Mapping a topic, finding gaps and refining key questions |
| Search | Comprehensive, several databases plus other sources | Streamlined (for example fewer databases, date or language limits) | Broad and mapping-oriented |
| Screening | Two reviewers, independently | One reviewer with a second reviewer checking a sample or the exclusions | Usually two reviewers, often iterative |
| Appraisal | Risk of bias required | Risk of bias required, sometimes simplified | Not usually done |
| Output | Evidence tables, GRADE profiles | Evidence summary with every shortcut stated | Evidence map or descriptive charting |
Rapid reviews. The Cochrane Rapid Reviews Methods Group’s updated guidance (2024) recommends involving the review’s end users when setting the question, prespecifying the streamlined methods in a protocol, and reporting every shortcut so that readers can judge the risk of missed evidence314. In a guideline report, list each shortcut next to the key question it affects.
Scoping reviews. A scoping review maps what evidence exists. It does not usually appraise study quality or estimate effects, so on its own it rarely supports a graded recommendation. It is most useful before the key questions are fixed. See how to write a scoping review, the PRISMA-ScR checklist explained and where to register a review protocol.
Grading evidence and recommendations
Many S3 guidelines use GRADE to rate the certainty of evidence for each outcome as high, moderate, low or very low. Certainty can be downgraded for risk of bias, inconsistency, indirectness, imprecision and publication bias, and upgraded in some cases, such as a large effect15. Other S3 guidelines use evidence levels such as the Oxford CEBM or SIGN schemes; the Leitlinienreport must state which system was used.
Recommendation strength is then expressed in standard German wording. The grades below are widely used in AWMF S3 guidelines, including negative forms for recommendations against an intervention1:
Table 3. Recommendation grades and standard wording commonly used in AWMF S3 guidelines
| Grade | German wording (for) | English meaning | German wording (against) | English meaning | Illustrative example (fictional) |
|---|---|---|---|---|---|
| A (strong recommendation) | soll | shall | soll nicht | shall not | “Adults with condition X shall (soll) be offered intervention Y.” |
| B (recommendation) | sollte | should | sollte nicht | should not | “Intervention Z should not (sollte nicht) be used routinely in condition X.” |
| 0 (open recommendation) | kann | may | kann verzichtet werden | may be omitted | “Intervention W may (kann) be considered for condition X.” |
The grade is not a mechanical translation of evidence certainty. The panel may grade up or down for reasons such as the balance of benefits and harms, patient preferences, applicability or resource use, and those reasons should be stated next to the recommendation. Many programmes also allow expert consensus (often labelled EK) recommendations where no adequate evidence was found; check how your guideline defines them.
Structured consensus and conflicts of interest
S3 recommendations are agreed through a structured consensus process, such as a nominal group technique, a structured consensus conference or a Delphi process, usually with neutral moderation. The panel must be representative of the intended users and should include patient representatives1. Consensus strength is reported for every recommendation, using the AWMF categories in Table 416.
Table 4. AWMF consensus strength categories
| Category | German term | Agreement among voting participants |
|---|---|---|
| Strong consensus | starker Konsens | >95% |
| Consensus | Konsens | >75% to 95% |
| Majority agreement | mehrheitliche Zustimmung | >50% to 75% |
| No majority agreement | keine mehrheitliche Zustimmung | ≤50% |
Conflicts of interest. Everyone involved must declare their interests. The declarations are assessed for relevance to the guideline topic and graded as low, moderate or high, with consequences that the Regelwerk sets out1:
Table 5. Conflict-of-interest categories and typical consequences under the AWMF Regelwerk
| Relevance | Typical consequence |
|---|---|
| Low | No leading role, such as coordinator or chair of a working group, on the affected topic |
| Moderate | Abstains from votes on recommendations related to the conflict (or a double vote with and without conflicted members, where the guideline’s methods allow it) |
| High | Excluded from discussion and voting on the related topics |
Evidence review teams are affected too: declare your own interests, keep the evidence work separate from the voting, and make sure the Leitlinienreport says how conflicts were assessed and managed.
Validity, updating and living guidelines
An AWMF guideline is valid for at most five years. After that it must be updated; otherwise it is flagged in the register as no longer current and is eventually archived15.
Living guidelines update individual recommendations as soon as relevant new evidence appears, so the unit of update is the recommendation, not the whole guideline17. In the AWMF register, a living guideline is registered for a maximum of five years and its update interval must be no longer than 12 months18. That depends on repeatable surveillance searches and rapid, well-documented evidence updates, often run as a living systematic review.
Worked example: from key question to graded recommendation
Illustrative example. The scenario below is fictional and shows the chain of documentation a guideline group will expect for one key question.
Table 6. One key question traced through an S3 evidence workflow (illustrative)
| Step | What the review team delivers | Where it is reported |
|---|---|---|
| 1. Key question | PICO: adults with condition X; intervention Y vs usual care; outcomes agreed with patient representatives (for example mortality, function, serious adverse events) | Leitlinienreport |
| 2. Search | Search for guidelines and systematic reviews, then an update search for randomised trials in at least two databases plus a trial registry; strategies, dates and limits recorded | Leitlinienreport appendix |
| 3. Selection | Two reviewers screen independently; exclusions with reasons; flow diagram | Leitlinienreport |
| 4. Appraisal | Risk of bias per study with a stated tool | Evidence tables |
| 5. Certainty | GRADE profile per outcome (for example moderate certainty for function, low for adverse events) | Evidence profile |
| 6. Consensus vote | Panel drafts “Intervention Y sollte be offered…” (grade B); votes, with conflicted members abstaining; result: consensus (for example 88%) | Guideline text and Leitlinienreport |
If a rapid review had been used for step 2, the team would add a line listing each shortcut (for example a single database or English-only limits) and how it might affect the conclusion.
Checklist for evidence review teams
Use this before delivering evidence to an S3 guideline group. It summarises the points above and complements the guideline group’s own methods plan1315.
S3 evidence delivery checklist
- Key questions are agreed with the guideline group and structured with PICO or an adapted framework.
- Outcomes are prioritised with patient representatives.
- The current Regelwerk version (2.2 as of November 2026) and the guideline’s methods plan have been checked.
- Search strategies, sources, dates and limits are fully documented.
- Inclusion criteria, screening process and reasons for exclusion are transparent.
- Risk of bias and certainty of evidence are assessed per outcome, with the system named.
- Any rapid-review shortcuts are listed against the key questions they affect.
- If existing guidelines were adopted or adapted, the method (for example ADAPTE or GRADE-ADOLOPMENT) is stated.
- Review team interests are declared.
- Evidence tables and profiles are ready for the Leitlinienreport.
Conclusion
S3 is the most demanding AWMF class: a systematic evidence review, transparent appraisal, structured consensus and managed conflicts of interest, all documented in the Leitlinienreport. As of November 2026, the reference points are Regelwerk 2.2 and, where IQWiG is commissioned, its evidence report methods.
Review teams that document every step, state every rapid-review shortcut and keep scoping reviews for refining questions give guideline groups evidence that is easier to assess and trust. For worked scenarios, see our review type and protocol case studies and the scoping review, PRISMA-ScR and AWMF Q&A.
Pubrica team verdict
For an S3 guideline, the review method matters less than whether every step and every shortcut can be traced from the key question to the voted recommendation in the Leitlinienreport.
Frequently asked questions
Sources
Sources were checked on 22 November 2026. Requirements and guidance may change after that date; confirm the current version with the issuing body.
- 1Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) – Ständige Kommission Leitlinien. AWMF-Regelwerk „Leitlinien“. Version 2.2 [Internet]. Berlin: AWMF; 2025 (summary of changes dated 2025 May 22) [cited 2026 Nov 22]. Available from: https://www.awmf.org/regelwerk
- 2Institute for Quality and Efficiency in Health Care (IQWiG). Evidence searches for medical guidelines [Internet]. Cologne: IQWiG; [cited 2026 Nov 22]. Available from: https://www.iqwig.de/en/presse/in-the-focus/evidence-searches
- 3Garritty C, Hamel C, Trivella M, Gartlehner G, Nussbaumer-Streit B, Devane D, et al. Updated recommendations for the Cochrane rapid review methods guidance for rapid reviews of effectiveness. BMJ. 2024;384:e076335. https://doi.org/10.1136/bmj-2023-076335
- 4Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Jahresbericht 2025 [Internet]. Berlin: AWMF; 2026 [cited 2026 Nov 22]. Available from: https://www.awmf.org/fileadmin/user_upload/dateien/publikationen/jahresberichte/AWMF-Jahresbericht_2025.pdf
- 5Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). AWMF guideline register [Internet]. [cited 2026 Nov 22]. Available from: https://register.awmf.org/
- 6Institute for Quality and Efficiency in Health Care (IQWiG). General Methods: Version 8.0 [Internet]. Cologne: IQWiG; 2025 Dec 19 (English version published 2026 Jul 1) [cited 2026 Nov 22]. Available from: https://www.iqwig.de/methoden/general-methods_version-8-0.pdf
- 7Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Generische Projektskizze für Evidenzberichte mit Fragestellungen zu Interventionen. Version 2.0 [Internet]. Köln: IQWiG; 2025 Jun 30 [cited 2026 Nov 22]. Available from: https://iqwig.de/printprodukte/generische-projektskizze-fuer-evidenzberichte-mit-fragestellungen-zu-interventionen_v2-0.pdf
- 8Leitlinienprogramm Onkologie (German Guideline Program in Oncology) of the AWMF, Deutsche Krebsgesellschaft and Deutsche Krebshilfe [Internet]. [cited 2026 Nov 22]. Available from: https://www.leitlinienprogramm-onkologie.de/
- 9Programm für Nationale VersorgungsLeitlinien (NVL) of the Bundesärztekammer, Kassenärztliche Bundesvereinigung and AWMF [Internet]. [cited 2026 Nov 22]. Available from: https://www.leitlinien.de/
- 10Abou-Dakn M, Schäfers R, Peterwerth N, Asmushen K, Bässler-Weber S, Boes U, et al. Vaginal birth at term - part 1. Guideline of the DGGG, OEGGG and SGGG (S3-level, AWMF registry no. 015/083, December 2020). Geburtshilfe Frauenheilkd. 2022;82(11):1143-93. https://doi.org/10.1055/a-1904-6546
- 11Bundesministerium für Gesundheit. Innovationsfonds [Internet]. Berlin: BMG; [cited 2026 Nov 22]. Available from: https://www.bundesgesundheitsministerium.de/service/begriffe-von-a-z/i/innovationsfonds.html
- 12Fervers B, Burgers JS, Voellinger R, Brouwers M, Browman GP, Graham ID, et al. Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation. BMJ Qual Saf. 2011;20(3):228-36. https://doi.org/10.1136/bmjqs.2010.043257
- 13Schünemann HJ, Wiercioch W, Brozek J, Etxeandia-Ikobaltzeta I, Mustafa RA, Manja V, et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol. 2017;81:101-10. https://doi.org/10.1016/j.jclinepi.2016.09.009
- 14Garritty C, Gartlehner G, Nussbaumer-Streit B, King VJ, Hamel C, Kamel C, et al. Cochrane Rapid Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews. J Clin Epidemiol. 2021;130:13-22. https://doi.org/10.1016/j.jclinepi.2020.10.007
- 15Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924-6. https://doi.org/10.1136/bmj.39489.470347.AD
- 16Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Dissolve-E FHIR implementation guide for the AWMF guideline registry: CodeSystem level of consensus [Internet]. [cited 2026 Nov 22]. Available from: https://fhir.awmf.org/awmf.ig/CodeSystem-cs-level-of-consensus.html
- 17Akl EA, Meerpohl JJ, Elliott J, Kahale LA, Schünemann HJ; Living Systematic Review Network. Living systematic reviews: 4. Living guideline recommendations. J Clin Epidemiol. 2017;91:47-53. https://doi.org/10.1016/j.jclinepi.2017.08.009
- 18Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Ausfüllhilfe zur Anmeldung eines Leitlinienvorhabens [Internet]. [cited 2026 Nov 22]. Available from: https://register.awmf.org/assets/documents/06_Ausfuellhilfe_Anmeldung.pdf
AWMFAWMF S3 guidelineAWMF RegelwerkRegelwerk 2.2S2e guidelineIQWiG evidence report
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation, so check its guide if it has one.
Dr. Charlie. (2026, November 22). AWMF S3 Guidelines: What the Rules Require from Systematic, Rapid and Scoping Reviews. Pubrica. https://pubrica.com/insights/regulatory-updates/awmf-s3-guidelines-evidence-reviews/
This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Next steps
Evidence reviews for German guideline groups
Pubrica’s systematic review team supports guideline groups with PICO key questions, documented searches, screening, risk of bias assessment, GRADE evidence profiles and rapid reviews that list every shortcut, in a format ready for the Leitlinienreport. We work to the group’s methods plan and the current AWMF Regelwerk but are not affiliated with or accredited by the AWMF. The guideline group keeps ownership of and responsibility for the recommendations, and timelines are agreed project by project.
This article is general information for researchers, not legal, regulatory or funding advice. Check the current requirements of your journal, funder, ethics committee or regulator before you act on it.
More in Regulatory Updates